leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   94 Trials   94 Trials   2090 News 


12345678910111213...3233»
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study. (Pubmed Central) -  Sep 24, 2024   
    Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Trial primary completion date:  PROSTSIZE: Prostatic Size Reduction Following of Leuprorelin Acetate (clinicaltrials.gov) -  Sep 19, 2024   
    P=N/A,  N=40, Recruiting, 
    Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies. Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  From Breast to Orbit: A Case Report of Metastatic Breast Cancer With Orbital Involvement. (Pubmed Central) -  Sep 17, 2024   
    Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.
  • ||||||||||  Erleada (apalutamide) / J&J
    THE ENCROACHING LESION: A CASE OF AN ENDOBRONCHIAL PROSTATE CANCER METASTASES (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6605;    
    Although exceedingly rare, endobronchial lesions can represent the initial presentation of metastatic non-pulmonary malignancies. Furthermore, this case highlights how robotic-assisted navigational bronchoscopy offers a promising avenue for obtaining precise biopsies of small sub-cm pulmonary lesions.
  • ||||||||||  carboplatin / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., paclitaxel / Generic mfg.
    THORACIC SMARCA4-DEFICIENT UNDIFFERENTIATED TUMOR: A CASE REPORT WITH MOLECULAR ANALYSIS (Convention Center 257 AB) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6098;    
    Thoracic SMARCA4-UT is a newly recognized aggressive thoracic malignancy and clinical awareness of this entity is necessary for early diagnosis. Further studies exploring immunotherapy and other targeted treatment options are needed.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Journal:  Testosterone recovery after androgen deprivation therapy. (Pubmed Central) -  Sep 7, 2024   
    GnRH antagonist use and younger age are associated with higher rates of T recovery after ADT. Longer ADT courses were associated with worse T recovery rates.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Prostatic Utricle Cysts as a Potential Pitfall in PSMA PET/CT Interpretation. (Pubmed Central) -  Aug 5, 2024   
    The patient then received intensity-modulated radiotherapy directed to 2 PSMA-avid pelvic nodes and leuprolide acetate, achieving an undetectable PSA in 4 months. This case highlights a potential pitfall in PSMA PET interpretation associated with prostatic utricle cysts.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    RECURRENT CATAMENIAL PNEUMOTHORAX: AN ILLUSTRATIVE CASE REPORT (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2810;    
    Multidisciplinary team involvement and a high index of suspicion are required to make the diagnosis. Multi-modal treatment with pleurodesis and hormonal suppression improves pneumothorax rate, but recurrence is common.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    IT'S NOT A ''MET!'': METACHRONOUS EYE CARCINOMA ON PREVIOUSLY METASTATIC BREAST CANCER (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2665;    
    Healthcare providers must monitor survivors of cancer for the potential development of MPM. Discussing follow-up plans and lifestyle modifications becomes essential to mitigate these risks and enhance the overall well-being of cancer survivors.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    A BREATH OF KNOWLEDGE: A CASE REPORT OF THORACIC ENDOMETRIOSIS SYNDROME (Convention Center Exhibit Hall: Rapid Fire Area 3D) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1980;    
    While VATS is the definitive diagnostic tool, negative pathology does not exclude TES, as observed in this case. Management entails hormonal suppressive therapy to mitigate recurrence risk, given the difficulty in eradicating thoracic endometrial implants.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
    METASTATIC PROSTATE ADENOCARCINOMA PRESENTING WITH ACUTE HYPOXIC RESPIRATOR FAILURE: A RARE PRESENTATION. (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1622;    
    Metastatic prostate adenocarcinoma presenting with hypoxic respiratory failure poses diagnostic and therapeutic challenges. Prompt recognition and appropriate management are crucial for optimizing patient outcomes.
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=32, Active, not recruiting, 
    Prompt recognition and appropriate management are crucial for optimizing patient outcomes. Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027
  • ||||||||||  thalidomide / Generic mfg.
    EFFECTS OF THALIDOMIDE IN THE TREATMENT OF EXPERIMENTAL ENDOMETRIOSIS IN RATS (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_2750;    
    In FET cycles, leuprorelin (as a GnRHa) downregulation combined with HRT may improve the clinical outcome of patients compared to the HRT cycle, especially for the clinical pregnancy and embryo implantation rates of patients with blastocyst transfer. In the model studied, thalidomide had ananalgesic, anti-inflammatory action and reduced the size of the implants, more significantlywith doses starting at 50 mg/kg/day, and can be suggested as an option in the treatment ofendometriosis pain.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial primary completion date, Combination therapy, Metastases:  Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) -  Jul 17, 2024   
    P2,  N=60, Active, not recruiting, 
    In the model studied, thalidomide had ananalgesic, anti-inflammatory action and reduced the size of the implants, more significantlywith doses starting at 50 mg/kg/day, and can be suggested as an option in the treatment ofendometriosis pain. Trial primary completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Review, Journal, Metastases:  Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm. (Pubmed Central) -  Jun 17, 2024   
    LHRH antagonists, such as degarelix, have also emerged...This review outlines pivotal trials leading to drug approvals in mHSPC and proposes a treatment decision algorithm for the same, based on statement from the Tuscan Interdisciplinary Uro-Oncological Group. A multidisciplinary approach is crucial to tailor treatment intensity and weigh risks and benefits effectively.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Infertility resolved after proper thoracic assessment: A case of disseminated endometriosis (PS-18; Poster board no. 19) -  May 31, 2024 - Abstract #ERS2024ERS_2325;    
    Gynecology started Leuprolide therapy...This case underscores the challenges of diagnosing and managing extra-pelvic endometriosis, emphasizing the need for a multidisciplinary approach. The patient's eventual pregnancy highlights the importance of timely and comprehensive management for complex endometriosis cases.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  A pediatric case of two Nicolau syndrome lesions following leuprolide injection in the upper extremity. (Pubmed Central) -  May 29, 2024   
    The fact that the development of NS cannot be detected in advance and the risk of rapid progression of tissue necrosis make disease management difficult. The prognosis of NS significantly depends on the patient, and when a developing lesion is noticed early, it is crucial to minimize the risk of complications.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  PROSTSIZE: Prostatic Size Reduction Following of Leuprorelin Acetate (clinicaltrials.gov) -  May 15, 2024   
    P=N/A,  N=40, Recruiting, 
    Patients received 6 Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Jul 2024
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    OVELIA  () -  May 8, 2024 - Abstract #BBCS2024BBCS_191;    
    The 3-monthly treatment showed greater hormonal and growth suppression effects, but there was no significant difference in PAH between the two groups. Sponsored by Tolmar.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
    MODULE 1: Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer (Hemisfair Ballroom 2) -  May 8, 2024 - Abstract #AUA2024AUA_4313;    
    Sponsored by Tolmar. This activity is CME-accredited by Research To Practice and supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Choline- and PSMA-PET Negative Oligo Pulmonary Metastasis in Prostate Adenocarcinoma (Exhibit Hall D - Science Pavilion (Convention Center); Screen 3; In-Person Only) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_634;    
    PSMA-PET performs less accurately in the evaluation of pulmonary metastasis compared to osseous, nodal, and other distant metastatic disease. Tissue sampling is recommended in equivocal cases, especially in the absence of other metastatic disease.